Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
106 Results for "
cd73
" in MedChemExpress (MCE) Product Catalog:
Products (106)
106 Results for "cd73" in MCE Product Catalog:
Cat. No.: HY-P8F029C
Synonyms: cd73,cd73-PE,AD2
Cat. No.: HY-P8F029F
Synonyms: cd73,cd73-PerCP,AD2
Cat. No.: HY-P8F029I
Synonyms: cd73,cd73-APC,AD2
Cat. No.: HY-P74272
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: NT5E; ENT; Prev. NT5; 5'-NT; IMP-Specific 5'-Nucleotidase; NTE; Thymidylate 5'-Phosphatase; 5'-Nucleotidase, Ecto (cd73); 5'-Deoxynucleotidase; Purine 5-Prime-Nucleotidase; Ecto-5'-Nucleotidase; 5' Nucleotidase (cd73); 5'-Nucleotidase; cd73 Antigen; CALJA
Species:
Human
Source:
HEK293
Cat. No.: HY-P77534
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: NT5E; ENT; Prev. NT5; 5'-NT; IMP-Specific 5'-Nucleotidase; NTE; Thymidylate 5'-Phosphatase; 5'-Nucleotidase, Ecto (cd73); 5'-Deoxynucleotidase; Purine 5-Prime-Nucleotidase; Ecto-5'-Nucleotidase; 5' Nucleotidase (cd73); 5'-Nucleotidase; cd73 Antigen; CALJA
Species:
Human
Source:
HEK293
Cat. No.: HY-P83708M
Synonyms: NT5E; NT5; NTE; 5'-nucleotidase; 5'-NT; Ecto-5'-nucleotidase; cd73
Cat. No.: HY-P8F029B
Synonyms: cd73,cd73-AF488,AD2
Cat. No.: HY-P8F029H
Synonyms: cd73,cd73-AF647,AD2
Cat. No.: HY-P8F029K
Synonyms: cd73,cd73-AF700,AD2
Cat. No.: HY-P8F029L
Synonyms: cd73,cd73-PC Blue,AD2
Cat. No.: HY-P8F029D
Synonyms: cd73,cd73-PE-Cy7,AD2
Cat. No.: HY-P8F029E
Synonyms: cd73,cd73-PE-CF596,AD2
Cat. No.: HY-P8F029J
Synonyms: cd73,cd73-APC-Cy7,AD2
Cat. No.: HY-P8F029G
Synonyms: cd73,cd73-PerCP-Cy5.5,AD2
Cat. No.: HY-184969
Research Areas:
NUCC-0227579 is a VHL-recruiting PROTAC degrader targeting CD73, with a DC50 of 0.32 μM. NUCC-0227579 synergistically mediates CD73 degradation through the ubiquitin-proteasome pathway and the lysosomal pathway. NUCC-0227579 inhibits the conversion of AMP to adenosine, abrogates adenosine-mediated immunosuppression, upregulates the activities of the NF-κB and NFAT pathways, and enhances the secretion, activation and proliferation levels of IFN-γ and TNF-α. NUCC-0227579 downregulates NAD + synthesis in tumor cells, and inhibits the proliferation, migration and adhesion abilities of tumor cells under glutamine-deficient conditions. NUCC-0227579 significantly suppresses tumor growth in a humanized NSG mouse model of triple-negative breast cancer .
Cat. No.: HY-100747R
CAS No.: 1802226-78-3
Target:
Research Areas:
PSB-12379 (Standard) is the analytical standard of PSB-12379 (HY-100747). This product is intended for research and analytical applications. PSB-12379, a nucleotide analogue, is a potent Ecto-5'-Nucleotidase (CD73) inhibitor with Kis of 9.03 nM (rat) and 2.21 nM (human) .
Cat. No.: HY-188081
CAS No.: 3112733-78-2
Target:
Research Areas:
YH-36400 is an orally bioavailable inhibitor of HIF-1α and HIF-2α. YH-36400 disrupts the dimerization of HIF-1α and HIF-1β and triggers proteasomal degradation, thereby inhibiting the transcriptional activities of HIF-1 and HIF-2. YH-36400 reduces the expression of PD-L1 and CD73, reprograms the tumor immune microenvironment, inhibits angiogenesis, and can be used in combination with immune checkpoint blockade therapy. YH-36400 is applicable to research related to breast cancer, lung cancer, melanoma, pancreatic cancer, colorectal cancer, prostate cancer, and head and neck squamous cell carcinoma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
